John W Hiemenz

John W Hiemenz, M.D.

Professor

Department: MD-HEMATOLOGY/ONCOLOGY
Business Phone: (352) 273-7832

About John W Hiemenz

John W. Hiemenz, M.D. is a board certified medical oncologist trained in adult and pediatric oncology, as well as infectious diseases, who has special interest and expertise in  the care and management of patients with hematological malignancies and those undergoing hematopoietic stem cell transplantation.  After his initial recruitment to join the bone marrow transplant faculty at UF in Gainesville as an assistant professor, Dr. Hiemenz moved to Tampa to help establish the newly formed Division of Bone Marrow Transplantation at the H. Lee Moffitt Cancer Center under the leadership of its founding director, Dr. Gerald Elfenbein (another former UF faculty member).  His subsequent academic appointments have included Professor and Co-Director of the Blood and Marrow Transplant Program at the Medical College of Georgia, and most recently Professor, and Director, Hematological Malignancies and BMT Program as well as Head, Infectious Diseases Research Program at the Feist-Weiller Cancer Center, LSU Health Sciences Center in Shreveport, Louisiana.  Dr. Hiemenz has recently returned to Gainesville and rejoins the faculty as Professor of Medicine to assist in the continued growth of the University of Florida/Shands Bone Marrow Transplant and Leukemia Program.

Teaching Profile

Courses Taught
2018
MDC7200 Medicine Clerkship
2018
MDC7203 Senior Medicine Clerk

Board Certifications

  • Internal Medicine
    American Board of Internal Medicine
  • Oncology
    American Board of Internal Medicine

Clinical Profile

Specialties
  • Oncology
Areas of Interest
  • Bone marrow transplant
  • Bone tumor
  • Cancer – resources
  • Leukemia
  • Leukemia – resources
  • Multiple myeloma
  • Non-Hodgkin lymphoma
  • Stem cell research

Publications

2021
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(7):757-767 [DOI] 10.1200/JCO.20.02259. [PMID] 33296242.
2020
Clinical predictors of delayed engraftment in autologous hematopoietic cell transplant recipients.
Hematology/oncology and stem cell therapy. 13(1):23-31 [DOI] 10.1016/j.hemonc.2019.08.003. [PMID] 31629722.
2020
Dietary Intake and Diet Quality of Hematopoietic Stem Cell Transplantation Survivors.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 26(6):1154-1159 [DOI] 10.1016/j.bbmt.2020.02.017. [PMID] 32105830.
2020
Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation.
Antimicrobial agents and chemotherapy. 64(4) [DOI] 10.1128/AAC.02467-19. [PMID] 32015031.
2020
Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes.
British journal of haematology. 189(5):e211-e213 [DOI] 10.1111/bjh.16629. [PMID] 32236943.
2019
A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients.
Blood advances. 3(12):1837-1847 [DOI] 10.1182/bloodadvances.2018028316. [PMID] 31208955.
2019
Survivor and Caregiver Expectations and Preferences Regarding Lung Cancer Treatment.
International journal of particle therapy. 6(2):42-49 [DOI] 10.14338/IJPT-19-00072.1. [PMID] 31998820.
2018
Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation.
Journal of clinical apheresis. 33(1):29-37 [DOI] 10.1002/jca.21556. [PMID] 28556233.
2017
Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
Pharmacogenetics and genomics. 27(5):190-196 [DOI] 10.1097/FPC.0000000000000277. [PMID] 28306618.
2016
A new model to predict remission status in AML patients based on day 14 bone marrow biopsy.
Leukemia research. 46:69-73 [DOI] 10.1016/j.leukres.2016.04.013. [PMID] 27132034.
2016
Association of mannose-binding lectin levels and invasive fungal disease in hematologic malignancy patients receiving myelosuppressive chemotherapy or allogeneic hematopoietic stem cell transplantation.
Bone marrow transplantation. 51(9):1228-32 [DOI] 10.1038/bmt.2016.92. [PMID] 27088382.
2016
Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience.
Clinical transplantation. 30(8):894-900 [DOI] 10.1111/ctr.12762. [PMID] 27219740.
2015
Poor Peripheral Blood Stem Cell Mobilization Correlates With Worse Long-Term Outcomes in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Biology of Blood and Marrow Transplantation. 21(2, 1) [DOI] 10.1016/j.bbmt.2014.11.175.
2015
Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial.
Transplant infectious disease : an official journal of the Transplantation Society. 17(6):831-7 [DOI] 10.1111/tid.12454. [PMID] 26346408.
2014
A Cyp2C19 Genotype Guided Dosing Approach for Optimizing Voriconazole in Patients With Ifis.
Pharmacotherapy. 34(10)
2014
Aztreonam for febrile neutropenia in patients with beta-lactam allergy.
Transplant infectious disease : an official journal of the Transplantation Society. 16(1):145-52 [DOI] 10.1111/tid.12148. [PMID] 24119095.
2013
Association of Mannose Binding Lectin (Mbl) Levels and Invasive Fungal Disease (Ifd) in Hematologic Malignancy Patients Undergoing Hematopoietic Stem Cell Transplantation (Hsct) Or Receiving Chemotherapy
Biology of Blood and Marrow Transplantation. 19(2):S226-S227 [DOI] 10.1016/j.bbmt.2012.11.274.
2012
A Phase I Study of the Vascular Disrupting Combretastatin, Oxi4503, in Patients With Relapsed and Refractory Acute Myeloid Leukemia (Aml) and Myelodysplastic Syndromes (Mds)
Blood. 120
2012
How I manage pulmonary nodular lesions and nodular infiltrates in patients with hematologic malignancies or undergoing hematopoietic cell transplantation.
Blood. 120(9):1791-800 [DOI] 10.1182/blood-2012-02-378976. [PMID] 22692506.
2012
Peripheral Blood Cd34(+) Specific Donor Chimerism Analysis as An Early Indicator of Disease Relapse After Allogeneic Hematopoietic Stem Cell Transplant in Patients With Myelodysplastic Syndromes and Acute Myelogenous Leukemia.
Blood. 120
2011
Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology.
Hematology/oncology clinics of North America. 25(1):101-16 [DOI] 10.1016/j.hoc.2010.11.008. [PMID] 21236393.
2010
Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 29(11):1387-94 [DOI] 10.1007/s10096-010-1013-0. [PMID] 20703506.
2010
Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology.
Infectious disease clinics of North America. 24(2):257-72 [DOI] 10.1016/j.idc.2010.01.010. [PMID] 20466269.
2009
Management of infections complicating allogeneic hematopoietic stem cell transplantation.
Seminars in hematology. 46(3):289-312 [DOI] 10.1053/j.seminhematol.2009.03.005. [PMID] 19549581.
2008
Population pharmacokinetics of micafungin in adult patients.
Diagnostic microbiology and infectious disease. 60(3):329-31 [PMID] 18024052.
2006
Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 43(8):1031-9 [PMID] 16983616.
2005
Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant.
Antimicrobial agents and chemotherapy. 49(4):1331-6 [PMID] 15793107.
2004
Adoptive immunotherapy with donor lymphocyte infusions and interleukin-2 after high-dose therapy and autologous stem cell rescue for multiple myeloma.
Bone marrow transplantation. 34(5):419-23 [PMID] 15286696.
2004
Infections due to emerging and uncommon medically important fungal pathogens.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 10 Suppl 1:48-66 [PMID] 14748802.
2004
Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 39(10):1407-16 [PMID] 15546073.
2003
Amphotericin B deoxycholate administered by continuous infusion: does the dosage make a difference?
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 36(8):952-3 [PMID] 12684905.
2001
Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 33(1):95-106 [PMID] 11389501.
2001
The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 33(11):1824-33 [PMID] 11692293.
2000
Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group.
Medicine. 79(4):250-60 [PMID] 10941354.
1999
A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy.
The New England journal of medicine. 341(5):305-11 [PMID] 10423464.
1999
Amphotericin B lipid complex in pediatric patients with invasive fungal infections.
The Pediatric infectious disease journal. 18(8):702-8 [PMID] 10462340.
1999
Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 29(6):1402-7 [PMID] 10585786.
1999
Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
The New England journal of medicine. 340(10):764-71 [PMID] 10072411.
1998
Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 26(6):1383-96 [PMID] 9636868.
1997
Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 24(4):635-42 [PMID] 9145737.
1997
Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE): a novel, intensive induction chemotherapy regimen for patients with high-risk multiple myeloma.
British journal of haematology. 96(4):746-8 [PMID] 9074417.
1997
High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency.
Bone marrow transplantation. 20(8):653-6 [PMID] 9383228.
1997
Nephrotoxicity of high-dose ifosfamide/carboplatin/etoposide in adults undergoing autologous stem cell transplantation.
The American journal of the medical sciences. 314(5):292-8 [PMID] 9365330.
1997
Nocardiosis after bone marrow transplantation: a retrospective study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 24(6):1154-60 [PMID] 9195074.
1996
Identification of an amphotericin B resistant strain of Candida albicans using a rapid 3H-glucose incorporation microassay.
The Journal of infection. 33(3):221-6 [PMID] 8945714.
1996
Lipid formulations of amphotericin B: recent progress and future directions.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 22 Suppl 2:S133-44 [PMID] 8722841.
1996
Methylobacterium bacteremia after infusion of contaminated autologous bone marrow.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 23(5):1191-2 [PMID] 8922835.
1996
Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.
Bone marrow transplantation. 18(1):9-14 [PMID] 8831989.
1996
Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients.
Infectious disease clinics of North America. 10(2):365-400 [PMID] 8803625.
1994
Evolving risk factors for invasive fungal infections–all neutropenic patients are not the same.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 18(5):793-8 [PMID] 8075273.
1994
High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion.
Seminars in oncology. 21(5 Suppl 12):86-92 [PMID] 7527592.
1994
Ifosfamide, carboplatin, and etoposide: a new regimen with a broad spectrum of activity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 12(3):544-52 [PMID] 8120552.
1993
Intensive dose ifosfamide, carboplatin, and etoposide followed by autologous stem cell rescue: results of a phase I/II study in breast cancer patients.
Surgical oncology. 2(1):87-95 [PMID] 7902764.
1993
Malassezia furfur folliculitis in cancer patients. The need for interaction of microbiologist, surgical pathologist, and clinician in facilitating identification by the clinical microbiology laboratory.
Annals of clinical and laboratory science. 23(5):377-84 [PMID] 8239485.
1993
Special considerations for the patient undergoing allogeneic or autologous bone marrow transplantation.
Hematology/oncology clinics of North America. 7(5):961-1002 [PMID] 8226568.
1993
The platelet-refractory bone marrow transplant patient: prophylaxis and treatment of bleeding.
Seminars in oncology. 20(5 Suppl 6):102-9 [PMID] 8211211.
1993
Two novel high-dose treatment regimens for metastatic breast cancer–ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities.
Seminars in oncology. 20(5 Suppl 6):59-66 [PMID] 8211217.
1993
When, how, what, and where to purge are not the questions either.
Journal of hematotherapy. 2(1):3-5 [PMID] 7921965.
1991
Rigors with vancomycin.
Annals of internal medicine. 115(4) [PMID] 1854124.
1990
A randomized trial of open lung biopsy versus empiric antimicrobial therapy in cancer patients with diffuse pulmonary infiltrates.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 8(2):222-9 [PMID] 2299367.
1990
Invasive fusariosis associated with an injury by a stingray barb.
Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology. 28(3):209-13 [PMID] 2213436.
1986
A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia.
The New England journal of medicine. 315(9):552-8 [PMID] 3526155.
1985
New beta-lactam antibiotics in granulocytopenic patients. New options and new questions.
The American journal of medicine. 79(2A):75-82 [PMID] 3895922.
1984
Approaching the controversies in antibacterial management of cancer patients.
The American journal of medicine. 76(3):436-49 [PMID] 6367456.
1984
Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies.
Annals of internal medicine. 100(5):663-71 [PMID] 6231873.

Grants

Feb 2022 ACTIVE
A Phase 1/2, Open-label, Multicenter Study to Evaluate a Dosing Regimen With Two Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (PF-06863135) Monotherapy in Participants with Relapsed/Refractory Multiple Myeloma
Role: Principal Investigator
Funding: SYNEOS HEALTH via PFIZER INC
Jul 2021 ACTIVE
Phase 1/2, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to Standard of Care for the Treatment of High-Risk Patients with Respiratory Viral Infections After Hematopoietic Cell Transplant
Role: Principal Investigator
Funding: MEDPACE via ALLOVIR
Jul 2020 ACTIVE
Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via JANSSEN RESEARCH AND DEVELOPMENT
May 2019 ACTIVE
A Phase III Randomized, Double-Blind Study of Maintenance Therapy with CC-5013 (NSC # 703813, IND # 70116) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma
Role: Principal Investigator
Funding: EASTERN COOP ONCOLOGY GROUP via NATL INST OF HLTH NCI
Mar 2019 ACTIVE
Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Stu
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU via NATL INST OF HLTH NCI
Sep 2018 – Jan 2023
A Phase 3, Randomized, Double-blind, Active Comparator-controlled, Multicenter Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Recipients of Allogeneic Hematopoietic Stem Cell Transplant (PNEU-STEM)
Role: Principal Investigator
Funding: DRUGDEV INC via MERCK SHARP & DOHME
Jul 2018 ACTIVE
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With Multiple Myeloma – The GENESIS Study
Role: Principal Investigator
Funding: CATO DRUG DEVELOPMENT via BIOLINE RX
Dec 2016 – Jul 2022
A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination with Dexamethasone in Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Pomalidomide and/or Daratumumab
Role: Principal Investigator
Funding: PRECISION ONCOLOGY via ONCOPEPTIDES AB
Apr 2016 – Jan 2022
A PHASE III STUDY OF POMALIDOMIDE AND LOW DOSE DEXAMETHASONEWITH OR WITHOUT PEMBROLIZUMAB (MK3475) IN REFRACTORY OR…..
Role: Principal Investigator
Funding: DRUGDEV INC via MERCK SHARP & DOHME
Aug 2015 – Sep 2017
A multi-center, randomized, double-blind, placebo controlled, study to evaluate the efficacy and safety of CSJ148 compared to placebo to prevent human cytomegalovirus (HCMV) replication in stem cell transplant patients
Role: Principal Investigator
Funding: NOVARTIS PHARMACEUTICALS CORP
Jul 2014 ACTIVE
Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age
Role: Principal Investigator
Funding: DANA FARBER CANCER INST
Nov 2013 – Nov 2017
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium difficile toxin A)
Role: Principal Investigator
Funding: Merck Sharp & Dohme
Nov 2013 – Jun 2017
A PHASE 3 RANDOMIZED STUDY OF THE EFFICACY & SAFETY OF POSACONAZOLE VERSUS VORICONAZOLE FOR THE TREATMENT……….
Role: Principal Investigator
Funding: Merck Sharp & Dohme
Nov 2013 – Oct 2016
A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents
Role: Principal Investigator
Funding: Merck Sharp & Dohme
Dec 2010 – Mar 2017
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs)
Role: Principal Investigator
Funding: Merck Sharp & Dohme

Education

Fellowship – Oncology and Infectious Diseases
1983 · National Cancer Institute
Internship – Internal Medicine
1979 · University of Iowa
Residency – Internal Medicine
1978-1980 · University of Iowa
Medical Degree
1974-1978 · University of Virginia, Charlottesville, VA

Contact Details

Phones:
Business:
(352) 273-7832
Emails:
Addresses:
Business Mailing:
PO Box 100278
GAINESVILLE FL 32610
Business Street:
UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE
1600 SW ARCHER RD
DIVISION OF HEMATOLOGY/ONCOLOGY
GAINESVILLE FL 326103003